Answers are grounded in this paper and cite their sources.
The clinical and immunologic effects of a biosynthetic human leukocyte interferon, recombinant leukocyte A interferon (IFL-rA), are reported in eight patients with advanced cancer. Single escalating doses from 3×106units to 198×106units were given by intramuscular injection in a phase 1 study. Major toxic effects included pyrexia, fatigue, myalgia, and headache. Data on the effects of IFL-rA on lymphocyte subpopulations and peripheral blood mononuclear-cell surface β2-microglobulin are presented. Four of eight patients had objective tumor regression, indicating that further investigation of this biologically active material is warranted. (JAMA1982;247:1718-1722)
No takes yet. Share an insight, caveat, or question.
S. J. Horning (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: